BP1.15205 promotes wakefulness in monkeys, ready for clinic

Sep. 17, 2025

At the 2025 World Sleep Congress, researchers from Bioprojet SA, Harmony Biosciences Holdings Inc. and Teijin Pharma Ltd. presented preclinical efficacy data on BP1.15205, a novel, orally available OX2R agonist under development for the treatment of narcolepsy.

BioWorld Science Conferences Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...